DelMar Pharmaceuticals Announces Successful Completion of End-of-Phase 2 Meeting with FDA on VAL-083

DelMar Pharmaceuticals (OTCQX:DMPI) announced the successful completion of an End of Phase 2 meeting with the U.S. Food and Drug Administration (FDA).
As quoted in the press release:

DelMar’s advanced development program will feature a single randomized Phase 3 study measuring survival outcomes compared to a “physicians’ choice” control, which, if successful, would serve as the basis for a New Drug Application (NDA) submission for VAL-083.   The control arm will consist of a limited number of salvage chemotherapies currently utilized in the treatment of Avastin-failed GBM. The final pivotal trial design will be confirmed with the FDA following further discussions with the Company’s clinical advisors.
The FDA confirmed that it will consider the totality of data available, including data obtained from DelMar’s other planned clinical trials in related GBM populations, when assessing the NDA.  The FDA also noted that DelMar can rely on prior US National Cancer Institutes (NCI) studies and historical literature to support non-clinical data required for an NDA filing and that DelMar will have the option to file under a 505(b)(2) strategy, which allows a sponsor to rely on already established safety and efficacy data in support an NDA.

DelMar Pharmaceuticals Chairman and CEO, Jeffrey Bacha, stated:

Our End-of-Phase 2 meeting was an important milestone for the Company as we advance the clinical development of VAL-083. We are pleased with the FDA’s guidance on our Phase 3 trial design in patients with glioblastoma who have failed prior therapy with temozolomide and bevacizumab (Avastin^®), and we look forward to finalizing the trial design and initiating the study as quickly as possible.
There is a major unmet medical need in refractory glioblastoma. The encouraging data from our clinical trials to date, combined with historical data from prior clinical trials from the NCI, suggest that VAL-083 has the potential to improve therapeutic outcomes for GBM patients who currently have no viable treatment options.  We are now one step closer to achieving that goal.

Connect with DelMar Pharmaceuticals (OTCQX:DMPI) to receive an Investor Presentation.